GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poxel SA (XPAR:POXEL) » Definitions » Current Deferred Revenue

Poxel (XPAR:POXEL) Current Deferred Revenue : €0.00 Mil (As of Dec. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Poxel Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Poxel's current deferred revenue for the quarter that ended in Dec. 2022 was €0.00 Mil.

Poxel Current Deferred Revenue Historical Data

The historical data trend for Poxel's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poxel Current Deferred Revenue Chart

Poxel Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Poxel Semi-Annual Data
Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Poxel Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Poxel's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Poxel (XPAR:POXEL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poxel SA (XPAR:POXEL) » Definitions » Current Deferred Revenue
Comparable Companies
XPAR:FALG XPAR:ALHYG XPAR:ALCOX XPAR:ALTHX XPAR:ALNFL XPAR:ALPAT XPAR:ALINT XPAR:ALVET XPAR:SIGHT XPAR:ALBPS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Website
https://www.poxel.com
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

Poxel (XPAR:POXEL) Headlines

No Headlines